FDA Warns Consumers About Potential Problems At Two Baltimore Pharmacies

Main Category: Regulatory Affairs / Drug Approvals
Also Included In: Public Health;  Pharmacy / Pharmacist
Article Date: 10 Aug 2008 - 0:00 PDT



Current ratings for:
'FDA Warns Consumers About Potential Problems At Two Baltimore Pharmacies'

Patient / Public:5 stars

5 (1 votes)

Healthcare Prof:not yet rated


The U.S. Food and Drug Administration is warning consumers who filled prescriptions at The Medicine Shoppe pharmacies located at 8035A Liberty Road and 5900 Reisterstown Road in Baltimore that they may have received drugs that were either expired or suspected counterfeit. The FDA is particularly concerned because a number of the drugs are for serious diseases and could have an adverse effect on treatment.

The products in question include:

-- Lisinopril (20 milligrams)
-- Guaifenesin/Dextromethorphan (600 mg and 1000 mg)
-- Gabapentin (100 mg, 300 mg and 400 mg)
-- Metoprolol (50 mg)
-- Nifedipine (30 mg)
-- Diclofenac Sodium (30 mg)
-- Glucophage (500 mg Extended Release)
-- Glucovance (125 mg and 500 mg)
-- Glipizide/Metformin (2.50 mg/250 mg)
-- Furosemide (20 mg)
-- Tamoxifen Citrate (10 mg)
-- Metformin HCl ER (500 mg)
-- Calcitrol (0.25 micrograms)

The FDA has no evidence that any other Medicine Shoppe pharmacies outside of the 8035A Liberty Road and 5900 Reisterstown Road facilities are involved.

Because the safety and efficacy of the listed drugs has not been established, the FDA is strongly advising consumers who filled prescriptions for these drugs at these two pharmacies to contact their prescribing physician immediately for new prescriptions. Additionally, consumers in possession of the above listed prescription drugs from these pharmacies should call FDA at 800-521-5783 for further information on how to dispose of the drugs.

Consumers and health care professionals can report adverse events to the FDA's MedWatch program at 800-FDA-1088, by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, Md 20852-9787, or online at www.fda.gov/medwatch/report.htm.

Article adapted by Medical News Today from original press release.
Visit our regulatory affairs / drug approvals section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
FDA. "FDA Warns Consumers About Potential Problems At Two Baltimore Pharmacies." Medical News Today. MediLexicon, Intl., 10 Aug. 2008. Web.
23 May. 2012. <http://www.medicalnewstoday.com/releases/117789.php>

APA
FDA. (2008, August 10). "FDA Warns Consumers About Potential Problems At Two Baltimore Pharmacies." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/117789.php.

Please note: If no author information is provided, the source is cited instead.



Add Your Opinion On This Article

'FDA Warns Consumers About Potential Problems At Two Baltimore Pharmacies'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Your Name:*
E-mail Address:*
Your Opinion Title:*
Opinion:*
This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.*

* Fields marked with a * need to be filled in before you hit the submit button.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




Regulatory Affairs / Drug Approvals

Most Popular Articles



Follow Our Regulatory Affairs News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Regulatory Affairs / Drug Approvals Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »